Clinical Trials
6 trialsNCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT05049148 2026-01-05
Platon
Fondation Ophtalmologique Adolphe de Rothschild
Phase NA Recruiting
NCT06887673 2025-03-20
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
University of South Florida
Phase EARLY_PHASE1 Not yet recruiting
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT01431326 2023-09-06
PTN_POPS
Duke University
Completed
NCT04634188 2020-11-18
Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study
Universitas Sumatera Utara
Completed